非编码RNA甲基化与肝癌发生发展关系研究进展*

doi:10.3969/j.issn.1672-5069.2018.06.042

实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (6): 991-994.doi: 10.3969/j.issn.1672-5069.2018.06.042

非编码RNA甲基化与肝癌发生发展关系研究进展^*

刘晓霓, 刘秀红综述, 陈德喜审校

100069北京市首都医科大学附属北京佑安医院北京市肝病研究所

收稿日期:2017-03-20 出版日期:2018-11-10 发布日期:2018-12-25
通讯作者: 陈德喜,E-mail:dexichen@ccmu.edu.cn
作者简介:刘晓霓,研究员,主要从事肝病基础与临床研究
基金资助:
*国家重大传染病防治协同创新项目（编号：2011协同创新中心）; 北京市卫生系统高层次卫生技术人才培养资助项目（编号：2015-3-101）; 北京市肝病研究所所内基金（编号：BJIH-01712）; 北京市市属医学科研院所公益发展改革试点项目（编号：京医研2016-2）

Non-coding RNA methylation in the carcinogenesis of hepatocellular carcinoma

Liu Xiaoni, Liu Xiuhong, Chen Dexi.

Institute of Hepatology,You'an Hospital,Capital Medical University,Beijing 100069

Received:2017-03-20 Online:2018-11-10 Published:2018-12-25

摘要/Abstract

摘要： 非编码RNA指不编码蛋白质的RNA,在生物体的生命活动中发挥着极广泛的调控作用。甲基化是从基因组层面研究RNA转录调控的重要领域,其中microRNA和lncRNA 甲基化异常可能是影响肝癌发生发展的关键信号。

关键词: 肝细胞癌, 非编码RNA, 甲基化, miRNA, lncRNA

Abstract: Non-coding RNAs （ncRNAs） refer to the RNAs that don't encode proteins,while play an important role in the life activities of organisms. Methylation is the significant part of RNA transcription based on genome. The abnormal methylation of microRNA and lncRNA may be the key signals to influence the occurrence and development of hepatocellular carcinoma （HCC）. In this paper,the implication of non-coding RNA（microRNA and lncRNA） methylation in the development of HCC in recent years is reviewed.

Key words: Hepatocellular carcinoma, Non-coding RNA, Methylation, miRNA, lncRNA

刘晓霓, 刘秀红综述, 陈德喜审校. 非编码RNA甲基化与肝癌发生发展关系研究进展^*[J]. 实用肝脏病杂志, 2018, 21(6): 991-994.

Liu Xiaoni, Liu Xiuhong, Chen Dexi.. Non-coding RNA methylation in the carcinogenesis of hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 991-994.

参考文献

[1] Previdi MC,Carotenuto P,Zito D,et al. Noncoding RNAs as novel biomarkers in pancreatic cancer:what do we know Future Oncol,2017,13(5):443-453.
[2] Zhang FF,Cardarelli R,Carroll J,et al.Physical activity and global genomic DNA methylation in a cancer-free population. Epigenetics,2011,6(3):293-299.
[3] Yuan SX,Zhang J,Xu QG,et al.Long noncoding RNA,the methylation of genomic elements and their emerging crosstalk in hepatocellular carcinoma. Cancer Lett,2016,379(2):239-244.
[4] Yu Z,Cheng AS.Epigenetic deregulation of microRNAs:new opportunities to target oncogenic signaling pathways in hepatocellular carcinoma. Curr Pharm Des,2013,19(7):1192-1200.
[5] Wu WR,Sun H,Zhang R,et al.Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1. Oncotarget,2016,7(14):18684-18693
[6] Cho WJ,Shin JM,Kim JS,et al.miR-372 regulates cellcycle and apoptosis of ags human gastric cancer cell line throughdirect regulation of LATS2. Mol Cells,2009,28:521-527.
[7] Wu G,Wang Y,Lu X,et al.Low mir-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma. BMC Cancer,2015,15:182.
[8] Yuan R,Zhi Q,Zhao H,et al.Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma. Tumour Biol,2015,36(4):3093-3100.
[9] Zhang Z,Zhang Y,Sun XX,et al.microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol Cancer,2015,14:5.
[10] Long XR,He Y,Huang C,et al.MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis. Int J Oncol,2014,44(6):1915-1922.
[11] Xie K,Liu J,Chen J,et al.Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. Gene,2014,543(1):101-107.
[12] Zhang J,Cheng J,Zeng Z,et al.Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. Oncotarget,2015,6(39):42040-42052.
[13] Xing TJ,Xu HT,Yu WQ,et al.Methylation regulation of liver-specific microRNA-122 expression and its effects on the proliferation and apoptosis of hepatocellular carcinoma cells. Genet Mol Res,2013,12(3):3588-3597.
[14] Song K,Han C,Zhang J,et al.Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology,2013,58(5):1681-1692.
[15] Wang L,Zhang X,Jia LT,et al.c-myc-mediated epigenetic silencing of microRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology,2014,59(5):1850-1063.
[16] Lu CY,Lin KY,Tien MT,et al.Frequent DNA methylation of miR-129-2 and its potential clinical implication in hepatocellular carcinoma. Genes Chromo Cancer,2013,52(7):636-643.
[17] Chen X,Zhang L,Zhang T,et al.Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int,2013,33(3):476-486.
[18] Wei X,Tan C,Tang C,et al.Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. Cell Signal,2013,25(5):1037-1043.
[19] Wei X,Xiang T,Ren G,et al.miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal,2013,25(2):439-446.
[20] Dohi O,Yasui K,Gen Y,et al.Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol,2013,42(2):411-418.
[21] Liu RF,Xu X,Huang J,et al.Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2. Cancer Lett,2013,329(2):164-173.
[22] Grossi I,Arici B,Portolani N,et al.Clinical and biological significance of miR-23b and miR-193a in human hepatocellular carcinoma. Oncotarget,2017,8(4):6955-6969.
[23] Cui S,Zhang K,Li C,et al.Methylation-associated silencing of microRNA-129-3p promotes epithelial-mesenchymal transition, invasion and metastasis of hepatocelluar cancer by targeting Aurora-A. Oncotarget,2016,7(47):78009-78028.
[24] Chen Z,Wang X,Liu R,et al.KDM4B-mediated epigenetic silencing of miRNA-615-5p augments RAB24 to facilitate malignancy of hepatoma cells. Oncotarget,2017,8(11):17712.
[25] Chu Y,Fan W,Guo W,et al.miR-1247-5p functions as a tumor suppressor in human hepatocellular carcinoma by targeting Wnt3. Oncol Rep,2017,38(1):343-351.

非编码RNA甲基化与肝癌发生发展关系研究进展^*

Non-coding RNA methylation in the carcinogenesis of hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[3]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[4]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[5]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[6]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[7]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[10]	幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.
[11]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[12]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.
[13]	王朝霞,关珂,付三仙,王慧杰. 肠内肠外联合营养支持治疗肝细胞癌患者围术期临床研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 272-275.
[14]	赵西太综述,聂青和审校. 循环microRNA早期诊断肝细胞癌研究现状及方法学探讨[J]. 实用肝脏病杂志, 2019, 22(2): 297-300.
[15]	范建高. 2018年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2019, 22(1): 1-3.